MeSH term
Frequency | Condition_Probility | Animals | 12 | 0.0 |
Humans | 67 | 0.0 |
Peptides/chemistry | 2 | 0.0 |
beta-Defensins/biosynthesis | 3 | 100.0 |
Cells, Cultured | 10 | 0.0 |
Keratinocytes/metabolism | 2 | 1.0 |
RNA, Messenger/analysis | 6 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 5 | 0.0 |
Adult | 16 | 0.0 |
Combined Modality Therapy | 2 | 0.0 |
Disease Progression | 2 | 0.0 |
Female | 31 | 0.0 |
Hydroxybutyrate Dehydrogenase/blood | 10 | 76.0 |
Male | 22 | 0.0 |
Middle Aged | 16 | 0.0 |
Risk Factors | 2 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 9 | 0.0 |
Aged | 8 | 0.0 |
Blotting, Western | 2 | 0.0 |
Dose-Response Relationship, Drug | 2 | 0.0 |
RNA, Messenger/metabolism | 2 | 0.0 |
Time Factors | 4 | 0.0 |
Fibroblasts/metabolism | 2 | 0.0 |
Interleukin-1/pharmacology | 2 | 0.0 |
Lipopolysaccharides/*pharmacology | 2 | 0.0 |
RNA, Messenger/genetics | 2 | 0.0 |
Research Support, Non-U.S. Gov't | 27 | 0.0 |
Tumor Necrosis Factor-alpha/pharmacology | 2 | 0.0 |
beta-Defensins/*genetics | 4 | 50.0 |
Biological Markers/analysis | 2 | 0.0 |
Comparative Study | 11 | 0.0 |
Interferon Type II/pharmacology | 2 | 0.0 |
Cell Count | 2 | 0.0 |
Interleukin-1/analysis | 2 | 2.0 |
Interleukin-8/analysis | 2 | 4.0 |
Gene Expression Regulation/*drug effects | 2 | 0.0 |
Hela Cells | 2 | 0.0 |
Protein Binding | 2 | 0.0 |
Aspartate Aminotransferases/blood | 6 | 4.0 |
Creatine Kinase/*blood | 4 | 10.0 |
English Abstract | 5 | 0.0 |
Isoenzymes | 12 | 6.0 |
L-Lactate Dehydrogenase/*blood | 7 | 24.0 |
Cell Line | 3 | 0.0 |
Cause of Death | 2 | 1.0 |
Double-Blind Method | 2 | 0.0 |
Prospective Studies | 2 | 0.0 |
Safety | 2 | 1.0 |
Treatment Outcome | 2 | 0.0 |
Creatine Kinase/blood | 5 | 4.0 |
L-Lactate Dehydrogenase/blood | 8 | 7.0 |
Base Sequence | 5 | 0.0 |
Gene Expression | 2 | 0.0 |
Molecular Sequence Data | 7 | 0.0 |
beta-Defensins/antagonists & inhibitors/*biosynthesis/genetics | 2 | 100.0 |
Coronary Artery Bypass/*adverse effects | 2 | 16.0 |
Hemolysis | 2 | 0.0 |
Molecular Weight | 2 | 0.0 |
beta-Defensins/*metabolism | 2 | 66.0 |
Amino Acid Sequence | 4 | 0.0 |
Ligands | 2 | 0.0 |
*Mutation | 2 | 0.0 |
Macromolecular Substances | 2 | 0.0 |
Prognosis | 2 | 0.0 |
Immunoblotting | 2 | 0.0 |
Child, Preschool | 4 | 0.0 |
Electrocardiography | 3 | 0.0 |
Hydroxybutyrate Dehydrogenase/*blood | 9 | 100.0 |
Kinetics | 3 | 0.0 |
Hydroxybutyrate Dehydrogenase/metabolism | 2 | 50.0 |
Tumor Markers, Biological/*blood | 2 | 0.0 |
Infant | 2 | 0.0 |
Infant, Newborn | 3 | 0.0 |
Myocardial Infarction/*enzymology | 4 | 57.0 |
Ovarian Neoplasms/*enzymology | 2 | 33.0 |
Immunohistochemistry | 5 | 0.0 |
Mice | 3 | 0.0 |
Mice, Nude | 2 | 0.0 |
Adolescent | 5 | 0.0 |
Child | 3 | 0.0 |
Polymerase Chain Reaction | 2 | 0.0 |
Dogs | 2 | 0.0 |
Liver Diseases/*enzymology | 2 | 15.0 |
*Enzyme Tests | 2 | 3.0 |
Heterozygote | 2 | 0.0 |
Bronchoalveolar Lavage Fluid/*chemistry | 2 | 3.0 |
